Rowlandmiller & PARTNERS.ADV Buys New Shares in Humacyte, Inc. (NASDAQ:HUMA)

Rowlandmiller & PARTNERS.ADV purchased a new position in Humacyte, Inc. (NASDAQ:HUMA) during the 4th quarter, Holdings Channel reports. The firm purchased 31,500 shares of the company’s stock, valued at approximately $159,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of Humacyte by 18.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after buying an additional 4,327 shares during the period. Rhumbline Advisers lifted its position in shares of Humacyte by 4.6% in the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock worth $578,000 after acquiring an additional 5,005 shares during the period. Private Advisor Group LLC lifted its position in shares of Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after acquiring an additional 6,510 shares during the period. SG Americas Securities LLC lifted its position in shares of Humacyte by 22.0% in the 4th quarter. SG Americas Securities LLC now owns 39,143 shares of the company’s stock worth $198,000 after acquiring an additional 7,069 shares during the period. Finally, Vontobel Holding Ltd. bought a new position in Humacyte in the fourth quarter worth $50,000. Institutional investors own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Tuesday, January 21st. Finally, Benchmark raised their price objective on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $3.55 on Monday. The stock has a market cap of $446.17 million, a PE ratio of -2.65 and a beta of 1.30. The business has a fifty day moving average of $4.42 and a two-hundred day moving average of $5.09. Humacyte, Inc. has a 52-week low of $2.81 and a 52-week high of $9.97.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.